HealthcareServices

Genomic Urine Testing Market Future Outlook 2026: Key Drivers and Growth Potential

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the genomic urine testing market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Genomic Urine Testing Market between 2026 and 2030?

The genomic urine testing market has witnessed rapid growth in recent years. It is anticipated to expand from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. This historical expansion can be attributed to advancements in molecular diagnostics, the increasing need for non-invasive testing, early biomarker research efforts, the adoption of genomic assays by laboratories, and the growth within oncology diagnostics.

The genomic urine testing market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $1.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.2%. Factors contributing to this growth during the forecast period include its incorporation into standard health screenings, its extended application in identifying infectious diseases, advancements in technological sensitivity, the increasing need for personalized monitoring, and thorough clinical validation studies. Key trends anticipated for this period encompass a greater acceptance of non-invasive diagnostic methods, a surge in the application of genomic biomarkers for disease identification, an escalating requirement for early cancer screening instruments, the broadening of personalized diagnostic strategies, and enhanced research into urinary genomic profiling.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Genomic Urine Testing Market?

The expanding prevalence of chronic kidney disease (CKD) is anticipated to propel the future growth of the genomic urine testing market. Chronic kidney disease refers to a condition where damaged kidneys can no longer effectively filter blood, resulting in an accumulation of waste and fluids in the body. The burden of chronic kidney disease is increasing primarily due to the rising incidence of diabetes, as high blood sugar levels harm kidney blood vessels, thereby impairing their ability to filter waste efficiently. Genomic urine testing supports chronic kidney disease management by facilitating the early detection of genetic markers, which allows for timely interventions and tailored treatment plans. This technology improves patient outcomes by enabling more accurate monitoring and slowing down disease progression. For instance, in November 2025, according to The American Journal of Managed Care, a US-based peer-reviewed medical publication, it was reported that 788 million adults aged 20 and older were living with CKD in 2023. Therefore, the escalating burden of chronic kidney disease is a key driver for the growth of the genomic urine testing market.

How Is The Genomic Urine Testing Market Organized Into Various Segments?

The genomic urine testing market covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

Which Trends Are Influencing The Development Of The Genomic Urine Testing Market?

Leading companies in the genomic urine testing market are concentrating on developing innovative solutions, such as next-generation sequencing, to improve the accuracy, sensitivity, and early detection capabilities of non-invasive diagnostic tests for various diseases. Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables the rapid, precise, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, unveiled the genomic urine test UroAmp. This test leverages next-generation deoxyribonucleic acid (DNA) sequencing to examine mutations in 60 genes associated with bladder cancer, facilitating early detection up to 12 years before clinical symptoms emerge. It offers detailed genetic insights to guide diagnosis, inform treatment decisions, and monitor recurrence, providing greater accuracy compared to traditional methods like cytology and cystoscopy.

Who Are The Major Companies Operating In The Genomic Urine Testing Market?

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Genomic Urine Testing Market?

North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Genomic Urine Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

Genetic Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-services-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Dna Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795